The €6 million (US$8 million) grant was provided to the Cardimmun consortium, consisting of Athera, Leiden University Medical Center, Turku PET Center, Clinical Trial Consultants and Smerud Medical Research

The €6 million (US$8 million) grant was provided to the Cardimmun consortium, consisting of Athera, Leiden University Medical Center, Turku PET Center, Clinical Trial Consultants and Smerud Medical Research

The results were scheduled to be presented by Henk Lokhurst, of the University Medical Center Utrecht, Netherlands, at the 18th Congress of the European Hematology Association, June 13-16 in Stockholm, Sweden

Medical Center 5/10/13 Jennerex Biotherapeutics Inc. (San Francisco) and Transgene SA (Strasbourg, France) Pexavec JX-594/TG6006, pexastimogene devacirepvec Advanced primary liver cancer Enrollment in the 120-patient Phase IIb study is complete 5/23/13 Lpath Inc. (San Diego) Asonep A humanized antibody designed to neutralize sphingosine-1-phosphate Renal cell carcinoma Began dosing in a Phase IIa trial 5/24/13 Macrogenics Inc. (Rockville, Md.) Margetuximab Next-generation anti-HER2 monoclonal

Forty-three patients who completed two years in the DIA-AID 1 study and who had residual beta cell function (stimulated C-peptide over 0.2 nmol/L) were enrolled into the open-label extension study at three medical centers in Israel, where they were treated with 1 mg of DiaPep277 quarterly for two consecutive years

Huntington's and Brains and Stem Cells For those cases where endogenous stem cells don't produce what is needed, meanwhile, researchers from the University of Rochester Medical Center have discovered a way to coax endogenous neural stem cells into producing medium spiny projection neurons, a type of neuron that is among those lost in Huntington's disease

Forty-three patients who completed two years in the DIA-AID 1 study and who had residual beta cell function (stimulated C-peptide over 0.2 nmol/L) were enrolled into the open-label extension study at three medical centers in Israel, where they were treated with 1 mg of DiaPep277 quarterly for two consecutive years...BrainStorm Cell Therapeutics Inc., of New York, said it submitted a favorable safety report to the institutional review board for the first group of patients in its ongoing Phase IIa

Another need is triage protocol, said Daniel Fagbuyi, disaster preparedness director at the Children's National Medical Center

Sirona Biochem Corp., of Vancouver, British Columbia, said it signed a letter of intent to create a collaboration with Cincinnati Children's Hospital Medical Center

The company's core technology was developed by Dror Mevorach, a scientist at Hadassah Medical Center and director of the Rheumatology Research Centre at Hadassah-Hebrew University Medical Center who specializes in the clearance of apoptotic cells

3SBio Inc., of Shenyang, China, said its shareholders voted in favor of the proposal to merge with Decade Sunshine Ltd. The merger would result in 3SBio becoming a privately held subsidiary of Decade Sunshine, with its American depository shares no longer listed on Nasdaq. The company's board previously recommended that shareholders vote to authorize the merger, and the parties expect to complete the deal as soon as practicable. Addex Therapeutics SA, of Geneva, said its gamma-aminobutyric

H5N1 is "just a couple of mutations away" from easy transmissibility," Albert Osterhaus, from the Dutch Erasmus Medical Center Department of Viroscience, told the panel audience

Another Bite at Leptin Scientists at the South Korean University of Ulsan Medical Center discovered a protein in the brain that is important for regulating feeding and appetite

The goals of the consortium, which includes three European university medical centers, are to develop a regulated gene expression system for glial cell-derived neurotrophic factor to improve the maintenance and survival of neurons as a Huntington's gene therapy and to develop regulated expression of artificial miRNA to conditionally silence the Htt gene

Baliopharm GmbH, a subsidiary of Baliopharm AG, of Basel, Switzerland, joined the NEU2 Consortium with a project addressing the recombinant manufacturing of an Fc-free bispecific CD20-CD95 antibody construct (Novotarg) with selectivity for activated B cells and efficacy studies in disease models relevant to multiple sclerosis therapy. The two-year project was funded by the German Federal Ministry of Education and Research. Bayer AG, of Leverkusen, Germany, signed an agreement to acquire the

The study, which was carried out at Erasmus University Medical Center in Rotterdam, found that a single intracoronary MPC infusion decreased infarct size in sheep by 40 percent, abrogated left ventricular adverse remodeling, reduced left ventricular volumes, increased small and larger blood vessel density by 71 percent (capillaries) and 127 percent (arterioles), and prevented heart failure

But in the work now published in Science Translational Medicine, Aboody, who is at the City of Hope National Medical Center & Beckman Research Institute, and her team engineered the cells to produce and secrete an enzyme that can convert the prodrug 5-fluorocytosine (5-FC) to the chemotherapy 5-fluorouracil (5-FU

How to Get from Diabetes to Heart Disease Scientists from Columbia University Medical Center have elucidated the molecular basis for the increased risk for heart disease that is one of the consequences of diabetes

Izun Pharmaceuticals Corp., of New York, expanded its ongoing Phase II trial assessing the effect of IZN-6N4, on oral mucositis (OM) to two additional medical centers, Memorial Sloan Kettering Cancer Center and Beth Israel Medical Center, a component of the Continuum Cancer Centers of New York